Key Takeaways
- • Ardian is exiting its majority stake in GBA Group, a Hamburg-based life sciences and laboratory analytics provider, to Bridgepoint in a transaction valued at over €1 billion, completing a five-year holding period that began in 2021.
- • Bridgepoint is acquiring the majority stake alongside GBA Group's management team, who will remain invested; minority investor Quadriga Capital is also exiting to Bridgepoint in the same transaction.
- • GBA Group has expanded significantly during Ardian's ownership, growing from 39 locations and 1,400 employees at acquisition in 2021 to more than 100 locations globally with over 3,500 employees across Europe, North America, and Southeast Asia.
- • The transaction is expected to close by end of 2026 subject to customary closing conditions and regulatory approvals; Ardian engaged Morgan Stanley and Macquarie in late 2025 to manage the sale process.
- • GBA Group serves over 60,000 customers across environmental, food, pharmaceuticals, chemicals, medical devices, and cosmetics markets, providing laboratory analysis, specialized clinical trial services, and consulting from its headquarters in Hamburg, Germany since its 1989 founding.
Summary
Ardian has agreed to divest its majority stake in GBA Group to Bridgepoint in a transaction valued at more than €1 billion, marking the exit from a five-year investment that commenced in 2021. The transaction represents a significant portfolio rotation for Ardian within the life sciences and laboratory analytics sector. Bridgepoint will acquire the majority stake alongside GBA Group's management team, who will retain their equity investment in the business. Quadriga Capital, which held a minority position, is also exiting alongside Ardian to the same buyer.
GBA Group is an international provider of laboratory analysis, specialized clinical trial services, and consulting headquartered in Hamburg, Germany, serving more than 60,000 customers globally. The company operates across approximately 100 locations worldwide and employs more than 3,500 people, delivering services to the environmental, food, pharmaceuticals, chemicals, medical devices, and cosmetics sectors. The platform has achieved substantial growth during Ardian's holding period, expanding from 39 locations with 1,400 employees at the time of Ardian's initial investment in 2021 to its current global footprint spanning Europe, North America, and Southeast Asia.
Ardian appointed Morgan Stanley and Macquarie in late 2025 to lead the sale process. The transaction is anticipated to close by the end of 2026, subject to customary closing conditions and regulatory approvals. Both Ardian and Bridgepoint declined to comment on the auction process, bidder competition, or specific bidding rounds. Financial details beyond the €1 billion valuation floor were not disclosed. The transaction was supported by comprehensive advisory teams, with Ardian's advisers including Milbank (legal), EY (financial due diligence), LEK (commercial due diligence), and Taxess (tax), while Bridgepoint engaged Citi, DC Advisory, and Rothschild (corporate finance), Latham & Watkins (legal), EY (financial and tax due diligence), and BCG (commercial due diligence).
GBA Group is an international provider of laboratory analysis, specialized clinical trial services, and consulting headquartered in Hamburg, Germany, serving more than 60,000 customers globally. The company operates across approximately 100 locations worldwide and employs more than 3,500 people, delivering services to the environmental, food, pharmaceuticals, chemicals, medical devices, and cosmetics sectors. The platform has achieved substantial growth during Ardian's holding period, expanding from 39 locations with 1,400 employees at the time of Ardian's initial investment in 2021 to its current global footprint spanning Europe, North America, and Southeast Asia.
Ardian appointed Morgan Stanley and Macquarie in late 2025 to lead the sale process. The transaction is anticipated to close by the end of 2026, subject to customary closing conditions and regulatory approvals. Both Ardian and Bridgepoint declined to comment on the auction process, bidder competition, or specific bidding rounds. Financial details beyond the €1 billion valuation floor were not disclosed. The transaction was supported by comprehensive advisory teams, with Ardian's advisers including Milbank (legal), EY (financial due diligence), LEK (commercial due diligence), and Taxess (tax), while Bridgepoint engaged Citi, DC Advisory, and Rothschild (corporate finance), Latham & Watkins (legal), EY (financial and tax due diligence), and BCG (commercial due diligence).
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.